



UNIVERSITY OF MASSACHUSETTS BOSTON

100 Morrissey Boulevard
Boston, MA 02125-3393
P: 617.287.5000
www.umb.edu

January 24, 2025

Center for Health Information and Analysis
501 Boylston Street
Boston, MA 02116

Dear CHIA DRC:

Thank you to the DRC for reviewing the application titled “Too many, too much, too young”: Trends of Pediatric Psychotropic Polypharmacy in Massachusetts Before and During the COVID-19 Pandemic (IRBNet ID: 2228515-1). Given recommendations by the committee following the DRC meeting on January 23, 2025, the following amendments are being made to the application:

- (1) The name of the study will be changed from ““Too many, too much, too young’: Trends of Pediatric Psychotropic Polypharmacy in Massachusetts Before and During the COVID-19 Pandemic” to “Trends of Pediatric Psychotropic Polypharmacy in Massachusetts Before and During the COVID-19 Pandemic.”
- (2) As a note to be added to the literature review, there may be other polypharmacy risk factors that are not represented by the MA APCD data, such as trauma history (Barnett & Concepcion Zayas, 2019), medical conditions (Carney et al. 2022), or genetic markers (Ghosh et al, 2022). These factors are not fully captured by the MA APCD data, highlighting the importance of considering comprehensive patient histories, including trauma exposure, co-occurring medical conditions, and socioeconomic context (Thomas et al., 2024), when assessing the risk of psychotropic polypharmacy in pediatric populations.

Sincerely,

A handwritten signature in black ink that reads "Gianna D'Ambrozio".

Gianna D'Ambrozio, LMSW
Ph.D. Candidate in Counseling Psychology
University of Massachusetts Boston
Email: Gianna.Dambrozio001@umb.edu

A handwritten signature in black ink that reads "Lisa Cosgrove".

Lisa Cosgrove, PhD
Clinical Psychologist, Professor, and Faculty Fellow at the Applied Ethics Center
University of Massachusetts Boston
Co-Founder of the Centre for Mental Health, Human Rights and Social Justice
Email: Lisa.Cosgrove@umb.edu

References

- Barnett, E. R., & Concepcion Zayas, M. T. (2019). High-risk psychotropic medications for US children with trauma sequelae. *Epidemiology and psychiatric sciences*, 28(4), 360–364.
- Carney, C., Parrott, L., Brown, K., Washington, L., Lebeschak, D., Busch, G., Hanna, J., Kvederis, K., Evans, L. Y., Williams, S., Zeilinger, V., Keogh, M., Walters, P., & Henschen, G. (2022). *Psychotropic drugs in children and adolescents: Clinical monograph*. Magellan Healthcare.
- Ghosh, P., Martinez, J., Shah, N., Kenan, W., Fowler, A., Limdi, N., Burns, L., Cogan, E. S., Gardiner, A., Hain, D., Johnson, H., Lewis, D., Shelton, R., & Liebelt, E. (2023). Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department. *Pediatric emergency care*, 39(1), 6–12.
- Thomas, K. C., Annis, I. E., deJong, N. A., Christian, R. B., Davis, S. A., Hughes, P. M., Prichard, B. A., Prichard, J. R., Allen, P. S., Gettinger, J. S., Morris, D. N., & Eaker, K. B. (2024). Association Between Neighborhood Context and Psychotropic Polypharmacy Use Among High-Need Children. *Psychiatric services (Washington, D.C.)*, appips20230639. Advance online publication. <https://doi.org/10.1176/appi.ps.20230639>